LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC

• Main Authors: Xinyin Liu (Author), Xiyi Lu (Author), Fuxi Zhen (Author), Shidai Jin (Author), Tongfu Yu (Author), Quan Zhu (Author), Wei Wang (Author), Kun Xu (Author), Jiaqi Yao (Author), Renhua Guo (Author)
• Format: Book
• Published: Elsevier, 2019-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor, has been used as the first choice of treatment for advanced non-small-cell lung cancer. However, during the course of treatment, cancer cells often develop resistance to gefitinib without fully understood mechanisms. In this...